Lecanemab Update: Predicting the future of Alzheimer's drugs
06/06/23 • 30 min
1 Listener
For the last episode of season 2, Dr. Mia talks about lecanemab, a monoclonal antibody against amyloid, results since the show's most popular episode on lecanemab released on 10/7/2022.
Lecanemab or Clarity AD clinical trial results in New England Journal of Medicine (NEJM)
Death related to lecanemab, reported in Science, related to Cerebral Amyloid Angiopathy
Donanemab press release by Lilly
Key points:
1) Aducanumab approval process eroded public's trust and careful screening for patients for real-world implementation of lecanemab is needed to build back trust.
2) Actual number of patients eligible for lecanemab will be much smaller than the total number of persons living with Alzheimer's disease in the country: studies estimate anywhere from 1% to 12% of patients seen in real world clinics.
3) Our healthcare infrastructure is not ready for early, timely, and accurate detection of Alzheimer's disease and tracking patients on monoclonal antibodies.
Video on Ask Dr. Mia YouTube channel
Transcripts on www.miayangmd.com. Transcripts are automatically generated and may contain minor inaccuracies.
Email: [email protected]
Opinions expressed are exclusive of Dr. Mia Yang and not reflective of her or guest speaker's employers or funders.
For the last episode of season 2, Dr. Mia talks about lecanemab, a monoclonal antibody against amyloid, results since the show's most popular episode on lecanemab released on 10/7/2022.
Lecanemab or Clarity AD clinical trial results in New England Journal of Medicine (NEJM)
Death related to lecanemab, reported in Science, related to Cerebral Amyloid Angiopathy
Donanemab press release by Lilly
Key points:
1) Aducanumab approval process eroded public's trust and careful screening for patients for real-world implementation of lecanemab is needed to build back trust.
2) Actual number of patients eligible for lecanemab will be much smaller than the total number of persons living with Alzheimer's disease in the country: studies estimate anywhere from 1% to 12% of patients seen in real world clinics.
3) Our healthcare infrastructure is not ready for early, timely, and accurate detection of Alzheimer's disease and tracking patients on monoclonal antibodies.
Video on Ask Dr. Mia YouTube channel
Transcripts on www.miayangmd.com. Transcripts are automatically generated and may contain minor inaccuracies.
Email: [email protected]
Opinions expressed are exclusive of Dr. Mia Yang and not reflective of her or guest speaker's employers or funders.
Previous Episode
Lewy Body Dementia with Dr. Trey Bateman
In this episode, Dr. Mia talks with Dr. Trey Bateman about Lewy Body dementia, unique challenges in diagnosis, different treatment options compared to Alzheimer's dementia, and his research on Mild Behavioral Impairment.
Dr. James (Trey) Bateman is a behavioral neurologist at Wake Forest University School of Medicine and the Salisbury Veterans Affairs Medical Center. His clinical care is spread across both Wake Forest and the Salisbury VA, where he focuses on the evaluation and care of people with neurodegenerative conditions, especially those with prominent neuropsychiatric symptoms. His research is focused on the role of chronic psychosocial stress and dementia risk and the role of early neuropsychiatric symptoms in the prodromal stages of neurodegenerative cognitive disorders.
More information on Dementia with Lewy Bodies
Anticholinergic medications based on the 2023 American Geriatrics Society Beers list of medications to use with caution in older adults
Support groups specifically for caregivers and persons living with Lewy Body Dementia
Video on Ask Dr. Mia YouTube channel
Transcripts on www.miayangmd.com. Transcripts are automatically generated and may contain minor inaccuracies.
Email: [email protected]
Opinions expressed are exclusive of Dr. Mia Yang and not reflective of her or guest speaker's employers or funders.
Next Episode
Biggest Dementia News You’ve Not Heard of
Returning back to Season 3 of Ask Dr. Mia Podcast talking about what is Comprehensive Dementia Care and Medicare's new program to pay for it.
Health Affairs' article on Comprehensive Dementia Care: https://www.healthaffairs.org/content/forefront/payment-comprehensive-dementia-care-five-key-recommendations
Medicare's GUIDE program: Guiding an Improved Dementia Experience: https://innovation.cms.gov/innovation-models/guide
D-CARE Study: https://www.dcare-study.org/
Video on Ask Dr. Mia YouTube channel
Transcripts on www.miayangmd.com. Transcripts are automatically generated and may contain minor inaccuracies.
Email: [email protected]
Opinions expressed are exclusive of Dr. Mia Yang and not reflective of her or guest speaker's employers or funders.
Ask Dr. Mia: Answers For Dementia Caregiving - Lecanemab Update: Predicting the future of Alzheimer's drugs
Transcript
Welcome to Ask Dr. Mia Podcast. This is episode number 26 and the last episode for season two. I started this podcasting journey about a year ago and have already finished two seasons. Thank you all for those who are listening and giving me support, whether it is through a comment, an email, or an Apple review. Thank you all very much.
I wanted to end this season two with an update on one of my most popular episodes that was released in the fall of 2022 right after Lecanemab, one of the ne
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/ask-dr-mia-answers-for-dementia-caregiving-210683/lecanemab-update-predicting-the-future-of-alzheimers-drugs-30490518"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to lecanemab update: predicting the future of alzheimer's drugs on goodpods" style="width: 225px" /> </a>
Copy